新辅助化疗对膀胱癌原发肿瘤与淋巴结转移灶间PD-L1染色一致性的影响
回顾性分析2008至2015年67例膀胱癌膀胱切除术后残留肿瘤且淋巴结阳性患者,评估原发灶与转移灶PD-L1染色一致性及新辅助化疗(NAC)的影响。肿瘤PD-L1 H评分一致率79.1%,联合阳性评分(CPS)一致率79.6%。NAC未显著影响PD-L1或CPS一致性。
要点
- 原发灶与淋巴结转移灶PD-L1 H评分一致率为79.1%,CPS一致率为79.6%。
- 新辅助化疗未显著影响PD-L1一致性(OR 1.974,95%CI 0.673-5.784)或CPS一致性(OR 0.500,95%CI 0.093-2.700)。
- 单因素分析中H评分和PD-L1染色强度与PD-L1一致性几率显著增加相关,染色强度在多因素分析中获证实。
核心结论
- 本研究中超过75%的病例原发膀胱肿瘤与淋巴结转移灶间PD-L1染色状态保持一致。
- 新辅助化疗未显示削弱这种维持PD-L1染色状态的倾向。
- 需要进一步标准化转移性膀胱癌中肿瘤和浸润免疫细胞的免疫组化,以改善治疗应用。
研究设计与样本
- 回顾性识别2008年至2015年间67例膀胱切除术后残留膀胱癌且淋巴结阳性的受试者。
- 采用H评分评估肿瘤细胞PD-L1染色,其中49例标本同时采用联合阳性评分(CPS)评估。
- 使用单因素和多因素logistic回归分析评估临床变量对原发灶与转移灶间PD-L1一致性的影响。
主要发现
- 肿瘤PD-L1染色一致率为79.1%,CPS一致率为79.6%。
- 新辅助化疗未显著影响PD-L1一致性(OR 1.974,95%CI 0.673-5.784)或CPS一致性(OR 0.500,95%CI 0.093-2.700)。
- 单因素分析中,H评分和PD-L1染色强度与PD-L1一致性几率显著增加相关,染色强度的关联在多因素分析中得到证实。
关键数值与推荐
- 肿瘤PD-L1 H评分一致率79.1%,CPS一致率79.6%。
- 新辅助化疗对PD-L1一致性的OR为1.974(95%CI 0.673-5.784),对CPS一致性的OR为0.500(95%CI 0.093-2.700)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate programmed death ligand 1 (PD-L1) staining fidelity between the primary tumor and associated lymph node metastases in bladder cancer. To secondarily evaluate whether neoadjuvant chemotherapy (NAC) affects this relationship. METHODS: Sixty-seven subjects with residual bladder cancer on cystectomy and associated positive lymph nodes were identified between 2008 and 2015. PD-L1 staining of tumor cells was evaluated using H score and 49 specimens were also evaluated using combined positive score (CPS). Univariable and multivariable logistic regression analysis were used to assess how various clinical variables affected odds of PD-L1 fidelity between primary and metastatic tumors. RESULTS: Tumor PD-L1 staining was concordant in 79.1% of cases and CPS was concordant in 79.6% of cases. NAC did not significantly impact odds of PD-L1 or CPS fidelity (OR 1.974, 95% CI 0.673-5.784, OR 0.500, 95% CI 0.093-2.700). Among clinical variables analyzed on univariable analysis of tumor PD-L1 fidelity, H-score, and PD-L1 staining intensity were associated with significantly increased odds of PD-L1 fidelity and the association with staining intensity was confirmed on multivariable analysis. CONCLUSION: PD-L1 fidelity between primary bladder tumors and nodal metastases was observed in >75% of cases in this study. Additionally, NAC was not shown to diminish this propensity to maintain PD-L1 staining status. Further standardization of immunohistochemistry of tumor and infiltrating imsmune cells in metastatic bladder cancer is needed to improve application of therapeutics.
引用
- Patel KR, Taylor BL, Khani F, et al. Impact of Neoadjuvant Chemotherapy on Concordance of PD-L1 Staining Fidelity between the Primary Tumor and Lymph Node Metastases in Bladder Cancer. Urology. 2019. PMID: 31201825. doi:10.1016/j.urology.2019.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。